PHAT
HealthcarePhathom Pharmaceuticals, Inc. · Biotechnology · $900M
What is Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals is a biopharmaceutical company focused on treatments for gastrointestinal diseases. Incorporated in 2018 and headquartered in Florham Park, New Jersey, it is building a commercial presence around a novel acid-blocking mechanism.
Phathom holds rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that works differently from traditional acid-suppression therapies. The company is advancing vonoprazan through Phase III trials for erosive gastroesophageal reflux disease and developing it in combination with antibiotics to treat Helicobacter pylori infection. Revenue generation depends on successful commercialization and regulatory milestones rather than a diversified product portfolio.
Phathom Pharmaceuticals was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
- Vonoprazan — a potassium-competitive acid blocker (P-CAB) for acid-related diseases
- Erosive GERD treatment program in Phase III clinical trials
- H. pylori eradication regimen combining vonoprazan with antibiotics
- Commercialization rights across the US, Europe, and Canada
Is PHAT a Good Stock to Buy?
UQS Score rates PHAT as Good overall, reflecting a mixed profile where one standout pillar contrasts with several areas of concern.
The Growth pillar is the clearest bright spot, reflecting the commercial and clinical momentum behind vonoprazan as it targets large, underserved patient populations in gastrointestinal disease. Valuation is rated Attractive, suggesting the market may not yet be fully pricing in the pipeline opportunity.
Quality, Moat, and Risk are all rated Weak — a combination typical of early-commercial-stage biotechs that carry meaningful execution, competitive, and financial risk.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PHAT pay dividends?
No — Phathom Pharmaceuticals, Inc. does not currently pay a dividend.
Phathom Pharmaceuticals does not pay a dividend. As an early-commercial-stage biopharmaceutical company, available capital is directed toward clinical development, regulatory submissions, and building out commercial infrastructure for vonoprazan. Income-focused investors should be aware that a dividend is unlikely in the near term.
When does PHAT report earnings?
Phathom Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed public companies.
As an early-commercial-stage company, quarterly results tend to reflect pipeline progress, commercialization costs, and cash runway rather than mature revenue trends. Key metrics to watch include vonoprazan prescription volumes and operating expense management.
For the most recent quarter's results, visit Phathom Pharmaceuticals' investor relations page directly.
What if I invested in Phathom Pharmaceuticals, Inc.?
Based on Phathom Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PHAT Long-term Outlook
The fundamental outlook for PHAT is shaped by its Strong Growth pillar and Attractive Valuation, set against Weak Quality, Moat, and Risk ratings. Vonoprazan's differentiated mechanism gives the company a potential foothold in a large acid-suppression market, but the path to sustained profitability carries meaningful uncertainty. Execution on commercialization and clinical milestones will be the primary determinants of whether the Growth pillar strength translates into durable business quality.
Growth drivers
- Vonoprazan's novel P-CAB mechanism targeting patients underserved by existing acid-suppression therapies
- Expansion of the H. pylori eradication program, broadening the addressable patient population
- Commercialization rights across three major markets — US, Europe, and Canada
Key risks
- Weak Risk pillar signals elevated financial and operational vulnerability typical of early-stage biotechs
- Weak Moat rating reflects limited competitive barriers if larger gastrointestinal players respond aggressively
- Valuation upside depends heavily on clinical and regulatory execution with little margin for setbacks
PHAT vs Peers
Phathom operates in a competitive specialty pharma and clinical-stage biotech landscape alongside several peers at similar development stages.
KalVista focuses on plasma kallikrein inhibitors for hereditary angioedema, a distinct therapeutic area from Phathom's gastrointestinal focus.
ORIC targets oncology resistance mechanisms, giving it a different risk and pipeline profile compared to Phathom's GI-centered approach.
Aktis concentrates on radiopharmaceuticals for cancer, placing it in a separate therapeutic category from Phathom's acid-blocking franchise.
Frequently Asked Questions
What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals develops and commercializes treatments for gastrointestinal diseases. Its lead asset is vonoprazan, a potassium-competitive acid blocker being advanced for erosive GERD and H. pylori infection. The company holds commercialization rights in the US, Europe, and Canada.
Does PHAT pay dividends?
No, PHAT does not currently pay a dividend. Capital is reinvested into clinical development and commercialization of vonoprazan. Dividend payments are not typical for early-commercial-stage biopharmaceutical companies.
When does PHAT report earnings?
Phathom Pharmaceuticals reports earnings on a quarterly cadence, standard for US-listed public companies. For exact dates and the most recent results, check the investor relations section of the company's official website.
Is PHAT a good stock to buy?
UQS Score rates PHAT as Good overall, driven by a Strong Growth pillar and Attractive Valuation. However, Weak ratings across Quality, Moat, and Risk highlight meaningful execution and financial uncertainty. The full pillar breakdown is available to UQS Pro members.
Is PHAT overvalued?
The UQS Valuation pillar for PHAT is rated Attractive, suggesting the current market price may not fully reflect the pipeline's potential. That said, valuation for clinical-stage biotechs is highly sensitive to trial outcomes and regulatory decisions.
How does PHAT compare to its competitors?
Peers like KalVista, ORIC Pharmaceuticals, and Aktis Oncology operate in different therapeutic areas — hereditary angioedema, oncology resistance, and radiopharmaceuticals respectively. Phathom's differentiation lies in its gastrointestinal focus and the novel P-CAB mechanism of vonoprazan.
What is PHAT's market cap bracket?
PHAT is classified as a small-cap stock. This places it in a segment of the market that can offer higher growth potential but typically carries greater volatility and liquidity risk compared to large- or mega-cap peers.
Who founded Phathom Pharmaceuticals?
Phathom Pharmaceuticals was incorporated in 2018. For detailed founding history and leadership background, the company's official investor relations page and SEC filings are the most reliable sources.
Is PHAT a long-term quality investment?
As a long-term quality indicator, PHAT's profile is mixed. The Strong Growth pillar points to meaningful pipeline opportunity, but Weak Quality, Moat, and Risk ratings suggest the business has not yet established the durable characteristics associated with long-term compounders. Pro members can view the complete analysis.
What is the main competitive advantage of Phathom Pharmaceuticals?
Phathom's primary differentiator is vonoprazan's potassium-competitive acid blocking mechanism, which works differently from the proton pump inhibitors that dominate the current market. Exclusive commercialization rights across three major geographies add to its positioning, though the Moat pillar is currently rated Weak.
What sector does PHAT belong to?
PHAT operates in the Healthcare sector, specifically within the biopharmaceutical and specialty gastrointestinal therapeutics space. Investors can explore other [Healthcare sector stocks](/sector/healthcare) rated by UQS Score for broader context.
Unlock Full PHAT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for all five dimensions
- ✓Access complete financial metrics and trend data
- ✓Compare PHAT against sector peers side by side
- ✓See the full risk and valuation breakdown in detail
- ✓Get the complete analyst-style quality profile for PHAT
Pro Analysis
PHAT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | 53.4 | 33.3 | 26.0 | 80.0 | 50.4 | 100.0 | +2.2 |
| May 7, 2026 | 51.2 | 33.3 | 26.0 | 80.0 | 39.0 | 97.1 | -0.5 |
| Apr 22, 2026 | 51.7 | 33.3 | 26.0 | 80.0 | 39.0 | 100.0 | -4.0 |
| Apr 2, 2026 | 55.7 | 33.3 | 26.0 | 100.0 | 39.0 | 100.0 | — |
PHAT — Pillar Breakdown
Quality
— 33.3/100 (25%)Phathom Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 80.0/100 (20%)Phathom Pharmaceuticals, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 50.4/100 (15%)Phathom Pharmaceuticals, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Phathom Pharmaceuticals, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 26/100 (25%)Phathom Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PHAT.
Score Composition
Financial Data
More Stock Analysis
How is the PHAT UQS Score Calculated?
The UQS (Unified Quality Score) for Phathom Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Phathom Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Phathom Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.